Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer

Sponsor

Biomea Fusion Inc. (Industry)

Overall Status

Recruiting

CT.gov ID

NCT05631574

Collaborator

(none)

Enrollment

Locations

Arms

56.6

Anticipated Duration (Months)

8.2

Patients Per Site

0.1

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

A Phase 1/1b dose finding study to determine the OBD(s) and RP2D(s) of BMF-219, a covalent menin inhibitor small molecule, in subjects with KRAS mutated unresectable, locally advanced, or metastatic NSCLC (Cohort 1), PDAC (Cohort 2), and CRC (Cohort 3).

Condition or Disease	Intervention/Treatment	Phase
Non Small Cell Lung Cancer Pancreatic Cancer Colorectal Cancer NSCLC PDAC CRC Relapsed Cancer Refractory Cancer Stage III Pancreatic Cancer Stage IV Pancreatic Cancer Stage III Non-small Cell Lung Cancer Stage IV Non-small Cell Lung Cancer Stage III Colorectal Cancer Stage IV Colorectal Cancer Stage III NSCLC Stage IV NSCLC KRAS Mutation-Related Tumors	Drug: BMF-219	Phase 1

Detailed Description

This is a dose finding study to determine the safety and tolerability, pharmacokinetics and pharmacodynamics, and clinical activity of escalating doses of BMF-219 administered orally (PO) either once daily (QD) or twice daily (BID) in 28-day cycles. After observing acceptable safety performance in these dosing regimens, additional subjects will be enrolled to assess efficacy in the determination of the OBD for use as a RP2D.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

90 participants

Allocation:

Non-Randomized

Intervention Model:

Sequential Assignment

Intervention Model Description:

This study is an ascending multiple dose clinical trial followed by cohort expansion. The dose escalation part is primarily intended to identify the optimal biologic dose (OBD)(s) of BMF-219 and to obtain initial safety and tolerability information regarding the compound when administered orally to subjects with KRAS mutated unresectable, locally advanced, or metastatic NSCLC, PDAC and CRC. This study will also evaluate the PK/PDn profiles of multiple dose administration of BMF-219. Following completion of the dose escalation, cohort and arm-specific expansion cohorts will commence in order to further confirm the safety and tolerability of BMF-219 dosed at or near the OBD.This study is an ascending multiple dose clinical trial followed by cohort expansion. The dose escalation part is primarily intended to identify the optimal biologic dose (OBD)(s) of BMF-219 and to obtain initial safety and tolerability information regarding the compound when administered orally to subjects with KRAS mutated unresectable, locally advanced, or metastatic NSCLC, PDAC and CRC. This study will also evaluate the PK/PDn profiles of multiple dose administration of BMF-219. Following completion of the dose escalation, cohort and arm-specific expansion cohorts will commence in order to further confirm the safety and tolerability of BMF-219 dosed at or near the OBD.

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Phase 1/1b Dose Finding Study of BMF-219, an Oral Covalent Menin Inhibitor, in Adult Patients With Unresectable, Locally Advanced, or Metastatic Non-small Cell Lung Cancer (NSCLC), Pancreatic Cancer (PDAC), and Colorectal Cancer (CRC)

Actual Study Start Date :

Jan 12, 2022

Anticipated Primary Completion Date :

Jun 1, 2025

Anticipated Study Completion Date :

Oct 1, 2026

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Escalation Phase Dose Escalation Phase will group all disease indications (NSCLC, PDAC, and CRC) together to assess the safety of each dose level. Participants will receive escalating dose BMF-219 orally once per day or twice per day to identify the OBD/RP2D (Optimal Biologic Dose/Recommended Ph2 Dose).	Drug: BMF-219 BMF-219 is an orally bioavailable, covalent small-molecule menin inhibitor.
Experimental: Expansion Phase Dose Expansion Phase will enroll additional subjects independently in each disease indication: Cohort 1: Participants with NSCLC Cohort 2: Participants with PDAC Cohort 3: Patients with CRC Cohorts 1, 2, and 3 will receive BMF-219 at the OBD/ RP2D to further assess the safety and efficacy of the investigational drug.	Drug: BMF-219 BMF-219 is an orally bioavailable, covalent small-molecule menin inhibitor.

Arm

Intervention/Treatment

Experimental: Escalation Phase

Dose Escalation Phase will group all disease indications (NSCLC, PDAC, and CRC) together to assess the safety of each dose level. Participants will receive escalating dose BMF-219 orally once per day or twice per day to identify the OBD/RP2D (Optimal Biologic Dose/Recommended Ph2 Dose).

Drug: BMF-219

BMF-219 is an orally bioavailable, covalent small-molecule menin inhibitor.

Experimental: Expansion Phase

Dose Expansion Phase will enroll additional subjects independently in each disease indication: Cohort 1: Participants with NSCLC Cohort 2: Participants with PDAC Cohort 3: Patients with CRC Cohorts 1, 2, and 3 will receive BMF-219 at the OBD/ RP2D to further assess the safety and efficacy of the investigational drug.

Drug: BMF-219

BMF-219 is an orally bioavailable, covalent small-molecule menin inhibitor.

Outcome Measures

Primary Outcome Measures

To determine the OBDs/RP2Ds of BMF-219 monotherapy in subjects with KRAS-driven unresectable, locally advanced, or metastatic NSCLC, PDAC and CRC. [30 months]
OBD/RP2D as determined by the number of subjects receiving BMF-219 monotherapy who experience Dose-Limiting Toxicities (DLTs) within each dose level. A DLT is defined as any clinically significant Adverse Event within 28 days of starting BMF-219 treatment and considered to be related to the IMP. Adverse Events will be assessed per CTCAE v5.0.
To determine the OBDs/RP2Ds of BMF-219 monotherapy in subjects with KRAS-driven unresectable, locally advanced, or metastatic NSCLC, PDAC and CRC. [30 months]
OBD/RP2D as measured by objective response rate (ORR). ORR will be assessed using RECIST 1.1 per investigator assessment.

Secondary Outcome Measures

To evaluate the safety and tolerability of BMF-219 monotherapy. [46 months]
Safety and tolerability will be determined using treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) as outcomes.
To evaluate the pharmacokinetics of BMF-219. [46 months]
Pharmacokinetics will be determined using maximum observed plasma concentration (Cmax ).
To evaluate the pharmacokinetics of BMF-219. [46 months]
Pharmacokinetics will be determined time to maximum plasma concentration (tmax).
To evaluate the pharmacokinetics of BMF-219. [46 months]
Pharmacokinetics will be determined using the AUC from time 0 to last quantifiable concentration (AUClast ).
To evaluate the efficacy of BMF-219 monotherapy in subjects with unresectable, locally advanced, or metastatic NSCLC, PDAC and CRC. [46 months]
Efficacy will be determined using duration of response (DOR), defined by the duration of time from the date of initial response of PR or better to the date of disease progression or death due to any cause, whichever occurs first. DOR will be assessed using RECIST 1.1 per investigator assessment.
To evaluate the efficacy of BMF-219 monotherapy in subjects with unresectable, locally advanced, or metastatic NSCLC, PDAC and CRC. [46 months]
Efficacy determined by disease control rate (DCR), defined as the proportion of response-evaluable subjects who maintain disease control (Complete Response, Partial Response or SD as per RECIST 1.1) from first dose through Week 6.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria

Adults with a confirmed diagnosis of unresectable, locally advanced and/or metastatic Stage IIIB/IV NSCLC, Stage III/IV PDAC and/or Stage III/IV CRC with no curative-intent treatment options and documented activating KRAS mutation (without known additional actionable driver mutations such as EGFR, ALK or ROS1)
Documented progression and measurable disease after ≥ 1 prior line of systemic therapy (≥ 2 and

≤ 4 prior lines for NSCLC) with adequate washout period and resolution of treatment-related toxicities to ≤ Grade 2

ECOG PS of 0-2 (0-1 for PDAC) and a life expectancy > 3 months in the opinion of the Investigator
Adequate hematological, liver, and renal function
Men and women of childbearing potential must use adequate birth control measures for the duration of the trial and at least 90 days after discontinuing study treatment

Exclusion Criteria

Symptomatic and/or untreated CNS or brain metastasis, pre-existing ILD or pericardial/pleural effusion of ≥ grade 2 or requiring chronic oxygen therapy for COPD or pleural effusions
Serious concomitant disorder including infection
Known positive test for HIV, HCV, HBV surface antigen
Concurrent malignancy in the previous 2 years
Prior menin therapy
Requiring treatment with a strong or moderate CYP3A inhibitor/inducer
Significant cardiovascular disease or QTcF or QTcB prolongation.
Major surgery within 4 weeks prior to first dose
Women who are pregnant or lactating.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	CTCA Clinical Research, LLC	Goodyear	Arizona	United States	85338
2	California Cancer Care Associates	Encinitas	California	United States	92024
3	University of California, San Diego	La Jolla	California	United States	92037
4	CTCA Clinical Research, LLC	Zion	Illinois	United States	60099
5	Washington University School of Medicine in St. Louis	Saint Louis	Missouri	United States	63110
6	Roswell Park Cancer Institute	Buffalo	New York	United States	14203
7	Ohio State Univeristy	Columbus	Ohio	United States	43210
8	MD Anderson	Houston	Texas	United States	77030
9	NEXT Oncology	San Antonio	Texas	United States	78229
10	NEXT Virginia	Fairfax	Virginia	United States	22031
11	Fred Hutch, University of Washington	Seattle	Washington	United States	98109